Oncology | |||
NO. | Nombre del producto | Especificación | Aprobado |
1 | Anastrozole | USP | DMF |
2 | Bicalutamide | USP | FDA approved |
3 | Bleomycin sulphate | USP | FDA/COS approved |
4 | Capecitabine | Enterprise standard | GMP/EDMF |
5 | Carboplatin | USP/EP | GMP/EDMF |
6 | Cisplatin | USP/EP | GMP/EDMF |
7 | Cladribine | USP | FDA approved |
8 | Cyclophosphamide | USP/EP | FDA/COS approved |
9 | Cytarabine | USP/EP | FDA/COS approved |
10 | Dacarbazine | USP | GMP/EDMF |
11 | Dactinomycin | USP | FDA approved |
12 | Daunorubicin hcl | USP/EP | FDA approved |
13 | Docetaxel | Enterprise standard | GMP/EDMF |
14 | Doxorubicin hcl | USP/EP | DMF/COS approved |
15 | Epirubicin hcl | EP | DMF/COS approved |
16 | Floxuridine | USP | FDA approved |
17 | Etoposide | USP | FDA approved |
18 | Fluorouracil | USP | GMP/DMF |
19 | Fludarabine phosphate | USP,EP | FDA/COS approved |
20 | Fulvestrant | Enterprise standard | GMP/EDMF |
21 | Gemcitabine hcl | EP | FDA approved |
22 | Glufosfamide | Enterprise standard | GMP |
23 | Granisetron hcl | USP, EP | FDA/COS approved |
24 | Idarubicin hcl | USP | FDA approved |
25 | Ifosfamide | USP | FDA approved |
26 | Irinotecan hcl | USP | GMP+EDMF |
27 | Letrozole | USP/ EP | GMP+EDMF |
28 | Leucovorin calcium | USP/EP | FDA approved |
29 | Leuprolide acetate | EP | EDMF |
30 | Mesna | EP | GMP/FDA/EDMF approved |
31 | Methotrexate | USP/EP | COA approved |
32 | Mitomycin | USP/EP | FDA/COS approved |
33 | Octreotide acetate | EP | EDMF |
34 | Oxaliplatin | EP | COS approved |
35 | Paclitaxel | USP | EDMF |
36 | Pfirarubicin | Enterprise standard | TDP |
37 | Pemetrexed disodium | Enterprise standard | GMP/EDMF |
38 | Tamoxifen citrate | USP,EP | EDMF |
39 | Valrubicin | Enterprise standard | TDP |
40 | Vinblastine sulphate | USP | GMP+DMF |
41 | Vincristine sulphate | USP,EP | GMP+DMF |
42 | Vinorelbine tartrate | USP,EP | FDA/COS approved |
Nota: Los productos cubiertos por una patente en el país de destino no será suministrado a este país. Sin embargo, la responsabilidad final y el riesgo recae en el comprador. |